Advertisement
Canada markets open in 1 hour 56 minutes

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7307
    -0.0013 (-0.18%)
     

  • CRUDE OIL

    82.81
    -0.55 (-0.66%)
     

  • Bitcoin CAD

    91,105.40
    +674.29 (+0.75%)
     

  • CMC Crypto 200

    1,434.52
    +10.42 (+0.73%)
     

  • GOLD FUTURES

    2,328.20
    -13.90 (-0.59%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,704.00
    +97.25 (+0.55%)
     

  • VOLATILITY

    15.84
    +0.15 (+0.96%)
     

  • FTSE

    8,083.91
    +39.10 (+0.49%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6836
    0.0000 (0.00%)
     

Nu Skin Enterprises (NUS) Lags Earnings; Beats on Sales - Tale of the Tape

Zacks Equity Research
Updated

Nu Skin Enterprises, Inc. (NUS) develops and distributes anti-aging personal care products and nutritional supplements and sells its products directly, as well as through its retail stores and website in Mainland China.


Multi-level marketer Nu Skin gets more than a third of its total revenue from Greater China, which includes Taiwan and Hong Kong. However, NUS has been witnessing a decline in Greater China sales since the past few quarters, as China’s laws are strict towards direct selling companies like Nu Skin. Other than that, Venezuela currency issues have also hurt Nu Skin’s revenues and earnings significantly in the past.


Analysts have been cautiously optimistic in the recent months about the company’s earnings and kept their estimates unchanged over the last 30 days. NUS does have a decent history when it comes to recent earnings reports as the stock has beaten estimates in three of the last four quarters, making for an average surprise of 5.48%.

ADVERTISEMENT


Currently, NUS has a Zacks Rank #3 (Hold), but that could definitely change following Nu Skin’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:


Earnings:  NUS posted earnings of 77 cents, worse than our consensus of 81 cents. Investors should note that these figures take out stock option expenses.


Revenue: NUS posted revenues of $609.6 million. This slightly exceeded our consensus estimate of $597 million.


Key Stats to Note: Nu Skin’s sales declined in double-digits from the prior-year quarter, with more than 50% decline seen in Greater China.


Check back later for our full write up on this NUS earnings report later!


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
NU SKIN ENTERP (NUS): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research